Cytomegalovirus reactivation is frequent in multiple myeloma patients treated with daratumumab-based regimens.

Our single-center retrospective experience showed that daratumumab might significantly increase the risk of CMV reactivation in MM, while currently underestimated and related to morbility and mortality in MM patients under treatments. However, further validation on larger and prospective clinical trials are required.